Brand name · Equine thymocyte immune globulin
Atgam: adverse event reports filed with FDA
612 reports list it as a suspect or interacting product, 2004–2026. Class: Immunoglobulin G.
- 612
- reports as suspect product
- 0% of all reports · about 27 a year
- 33
- reports, 12 months to June 2026
- 28 in the 12 months before
- 93.6%
- marked serious by the reporter
- 97.1% across the class
- 23.9%
- record death among outcomes, as reported
- 146 reports · not verified by FDA
Between February 2004 and June 2026, 612 adverse event reports received by FDA list the brand name Atgam (equine thymocyte immune globulin) as a suspect or interacting product. Reports that mention it only as a concomitant medication (208) are left out of every figure here.
In the 12 months to June 2026, 33 reports listed it, up 18% from 28 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 27 reports a year and 0% of the 20,646,523 reports in the database, and 6.9% of the reports for the immunoglobulin G class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded pyrexia (13.6%), acute kidney injury (5.7%) and hypertension (5.2%). A report can list several reactions, so shares add to more than 100%; 285 different terms appear across these reports. Pyrexia is recorded in 13.6% of these reports, a larger share than in the median immunoglobulin G drug (10.3%).
93.6% of the reports are marked serious by the reporter (97.1% across the class); 23.9% record death among the outcomes and 31.5% record hospitalisation, as reported. 37.4% of the reports came from physicians, and the largest patient age group is 45 to 64 (20.8%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Atgam reports recording the termmedian drug in immunoglobulin g
- Pyrexiafever13.6%83
- Acute kidney injurysudden loss of kidney function5.7%35
- Hypertensionhigh blood pressure5.2%32
- Drug ineffectivethe medicine did not work as expected5.1%31
- Sepsisa severe body-wide response to infection3.8%23
- Serum sickness3.8%23
- Haemoglobin decreasedlow haemoglobin3.6%22
- Toxicity to various agentspoisoning or toxic effect of one or more substances3.6%22
- Infusion related reactiona reaction during or soon after an infusion3.4%21
- Urticariahives3.4%21
- Rashskin rash3.3%20
- Treatment failurethe treatment did not work3.3%20
- Septic shockshock arising from infection3.1%19
- Platelet count decreasedlow platelet count2.8%17
- Chillschills or shivering2.6%16
- Disease progressionthe disease advanced2.6%16
- Renal failurekidney failure2.5%15
- Abdominal pain upperupper stomach pain2.3%14
- Aplastic anaemia2%12
- Headachehead pain2%12
- Off label useused for a purpose or in a way not on the label2%12
- Central hypothyroidism1.8%11
- Product use in unapproved indicationused for a purpose not on the label1.8%11
- White blood cell count decreasedlow white cell count1.8%11
- Atrial fibrillationan irregular heart rhythm1.6%10
- Deaththe patient died; cause not stated by this term1.6%10
- Dyspnoeashortness of breath1.6%10
- Mucosal inflammation1.6%10
Top 30 of 285 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 3 drugs in the immunoglobulin g class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 8,877 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 21.7% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Aplastic anaemia | 252 | 41.2% |
| Bone marrow failure | 67 | 10.9% |
| Bone marrow conditioning regimen | 13 | 2.1% |
| Immunosuppressant drug therapy | 13 | 2.1% |
| Stem cell transplant | 9 | 1.5% |
| Renal transplant | 8 | 1.3% |
The indication field is filled in by the reporter and is often blank; shares are of all 612 reports.
In context
| Measure | Atgam | Immunoglobulin G | All reports |
|---|---|---|---|
| Reports as suspect product | 612 | 8,877 | 20,646,523 |
| Share of that pool | — | 6.9% | 0% |
| Reports, latest 12 months | 33 | — | 1,332,454 |
| Marked serious | 93.6% | 97.1% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 239 | 279 | 91 |
| Hospitalisation recorded, per 1,000 reports | 315 | 346 | 213 |
| Consumer-filed share | 13.1% | 4.4% | 45.8% |
| Top term, share of reports | Pyrexia 13.6% | median 10.3% | 1.6% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the immunoglobulin g class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Thymoglobulin | brand | 6,283 | 308 | 97% |
| Anti-thymocyte globulin (rabbit) | generic | 1,982 | 260 | 98.8% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Atgam reports
How many adverse event reports has FDA received for Atgam?
612 reports list Atgam as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 33 of them arrived in the latest 12 months. Another 208 list it only as a concomitant medication.
What reactions are recorded in Atgam reports?
pyrexia (13.6%), acute kidney injury (5.7%), hypertension (5.2%), drug ineffective (5.1%) and sepsis (3.8%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Atgam was responsible.
How serious are the reports?
93.6% are marked serious by the reporter. Among the outcomes recorded, 23.9% of reports include death and 31.5% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (37.4%), other health professional (31%) and pharmacist (16.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Atgam rising?
33 reports in the 12 months to June 2026, up 18% from 28 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Atgam was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Atgam?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Atgam as a suspect or interacting product; reports listing it only as a concomitant medication (208) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.